VEGFA and Pseudoxanthoma elasticum: The pharmaceutical agents, bevacizumab and ranibizumab, antagonists of VEGF, which were initially tested, hold promise for long-term control of choroid neovascularization in PXE, and intravitreal injections of other VEGF antagonists, for example aflibercept, have been recently presented to be effective in prevention of loss of visual acuity [55].